{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:20Z","timestamp":1792979900612,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","award":["2025"],"award-info":[{"award-number":["2025"]}],"id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean Society of Gastroenterology funded by the Korea Research Foundation of Internal Medicine","award":["KJG-2023-05"],"award-info":[{"award-number":["KJG-2023-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12072-025-10809-3","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:20:31Z","timestamp":1741432831000},"page":"959-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis"],"prefix":"10.1007","volume":"19","author":[{"given":"Jae-Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0381","authenticated-orcid":false,"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"10809_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3350\/cmh.2022.0422","volume":"29","author":"SC Huang","year":"2023","unstructured":"Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives. Clin Mol Hepatol. 2023;29:320\u2013331","journal-title":"Clin Mol Hepatol"},{"issue":"1348\u20131355","key":"10809_CR2","volume":"17","author":"HW Lee","year":"2019","unstructured":"Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, et al. Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection. Clin Gastroenterol Hepatol. 2019;17(1348\u20131355): e1342","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10809_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/infdis\/jiu471","volume":"211","author":"US Gill","year":"2015","unstructured":"Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211:374\u2013382","journal-title":"J Infect Dis"},{"key":"10809_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3350\/cmh.2022.0028","volume":"28","author":"HY Lin","year":"2022","unstructured":"Lin HY, Tseng TC. Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: facts and puzzles. Clin Mol Hepatol. 2022;28:181\u2013182","journal-title":"Clin Mol Hepatol"},{"key":"10809_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u2013195","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10809_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s12072-023-10528-7","volume":"17","author":"EG Hwang","year":"2023","unstructured":"Hwang EG, Jung EA, Yoo JJ, Kim SG, Kim YS. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int. 2023;17:860\u2013869","journal-title":"Hepatol Int"},{"key":"10809_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10664-8","author":"JW Park","year":"2024","unstructured":"Park JW, Yoo JJ, Kim SG, Kim YS. Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int. 2024. https:\/\/doi.org\/10.1007\/s12072-024-10664-8","journal-title":"Hepatol Int"},{"key":"10809_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.17998\/jlc.2022.12.30","volume":"23","author":"D Daher","year":"2023","unstructured":"Daher D, Dahan KSE, Singal AG. Non-alcoholic fatty liver disease-related hepatocellular carcinoma. J Liver Cancer. 2023;23:127\u2013142","journal-title":"J Liver Cancer"},{"key":"10809_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.17998\/jlc.2022.09.18","volume":"22","author":"W Jang","year":"2022","unstructured":"Jang W, Lee HW, Lee JS, Kim BK, Kim SU, Park JY, et al. Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology. J Liver Cancer. 2022;22:158\u2013166","journal-title":"J Liver Cancer"},{"key":"10809_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u2013681","journal-title":"J Hepatol"},{"issue":"427\u2013437","key":"10809_CR11","volume":"20","author":"KS Byun","year":"2022","unstructured":"Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20(427\u2013437): e425","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10809_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261760","volume":"17","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE. 2022;17: e0261760","journal-title":"PLoS ONE"},{"key":"10809_CR13","doi-asserted-by":"publisher","first-page":"135965352210823","DOI":"10.1177\/13596535221082399","volume":"27","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: a prospective real-world clinical study. Antivir Ther. 2022;27:13596535221082400","journal-title":"Antivir Ther"},{"key":"10809_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/hiv.12984","volume":"22","author":"L Gazzola","year":"2021","unstructured":"Gazzola L, Tagliaferri G, De Bona A, Mondatore D, Borsino C, Bini T, et al. Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance? HIV Med. 2021;22:140\u2013145","journal-title":"HIV Med"},{"key":"10809_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/ofid\/ofab621","volume":"9","author":"PWG Mallon","year":"2022","unstructured":"Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis. 2022;9:621","journal-title":"Open Forum Infect Dis"},{"key":"10809_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3350\/cmh.2021.0314","volume":"28","author":"J Jeong","year":"2022","unstructured":"Jeong J, Shin JW, Jung SW, Park EJ, Park NH. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin Mol Hepatol. 2022;28:254\u2013264","journal-title":"Clin Mol Hepatol"},{"key":"10809_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"AA Shaheen","year":"2017","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599\u2013604","journal-title":"Aliment Pharmacol Ther"},{"key":"10809_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441\u2013453","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10809_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","volume":"16","author":"A Mills","year":"2016","unstructured":"Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43\u201352","journal-title":"Lancet Infect Dis"},{"key":"10809_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","volume":"56","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168\u2013180","journal-title":"J Gastroenterol"},{"key":"10809_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1126\/scisignal.272re3","volume":"2","author":"RL Silverstein","year":"2009","unstructured":"Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:3","journal-title":"Sci Signal"},{"key":"10809_CR22","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.2337\/db07-0907","volume":"56","author":"DP Koonen","year":"2007","unstructured":"Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56:2863\u20132871","journal-title":"Diabetes"},{"key":"10809_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/ATVBAHA.107.161653","volume":"28","author":"V Luangrath","year":"2008","unstructured":"Luangrath V, Brodeur MR, Rhainds D, Brissette L. Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo. Arterioscler Thromb Vasc Biol. 2008;28:1290\u20131295","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10809_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.M011981","volume":"52","author":"M Brundert","year":"2011","unstructured":"Brundert M, Heeren J, Merkel M, Carambia A, Herkel J, Groitl P, et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res. 2011;52:745\u2013758","journal-title":"J Lipid Res"},{"key":"10809_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70187","volume":"97","author":"LY Kim","year":"2025","unstructured":"Kim LY, Kim JY, Yoo JJ, Kim SG, Kim YS. Tenofovir disoproxil fumarate versus entecavir: effects on lipid profiles and cardiovascular outcomes in people living with chronic hepatitis B. J Med Virol. 2025;97: e70187","journal-title":"J Med Virol"},{"key":"10809_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/apt.17764","volume":"59","author":"SK Fung","year":"2024","unstructured":"Fung SK, Pan CQ, Wong GL, Seto WK, Ahn SH, Chen CY, et al. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Aliment Pharmacol Ther. 2024;59:217\u2013229","journal-title":"Aliment Pharmacol Ther"},{"key":"10809_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3350\/cmh.2023.0328","volume":"30","author":"H Hong","year":"2024","unstructured":"Hong H, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, et al. Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide. Clin Mol Hepatol. 2024;30:49\u201363","journal-title":"Clin Mol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10809-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:34:49Z","timestamp":1760074489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10809-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10809"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10809-3","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol received approval from the Institutional Review Board of Soonchunhyang University Bucheon Hospital (SCHBC 2023-07-016-001, date of registration 23-September-2023), and adhered to the ethical guidelines of the World Medical Association Declaration of Helsinki. Informed consent requirement was waived by the IRB of Soonchunhyang University Bucheon Hospital due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}